Vir initiates open-label Phase 2 study for experimental hepatitis B treatment
Shares of Vir Biotechnology Inc.
VIR,
+1.04%
gained 0.6% in trading on Thursday after the company said it started an open-label Phase 2 clinical trial for its experimental hepatitis B treatment. The study combines two investigational therapies with the…
